VT
$30.33
-0.24
(-0.79%)
As of Oct 5, 2026, 5:14 PM EDT
Price history
vTv Therapeutics (VTVT) is trading down at $30.33 (-0.79%), as of the latest quote. It operates in the Health Care sector.
IPO: July 30, 2015 · $15.00 offering · NASDAQ · View IPO details →
vTv Therapeutics revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $634.0K | $291.0K | $12.4M | $2.76M | $6.41M | $4.00M | $2.02M | $0 | $1.02M | $0 |
| Growth (year over year) | +22.2% | −54.1% | +4172.9% | −77.8% | +132.1% | −37.6% | −49.6% | −100.0% | — | −100.0% |
| Operating income | −$55.0M | −$50.7M | −$19.8M | −$20.9M | −$11.9M | −$21.7M | −$22.5M | −$25.5M | −$24.2M | −$32.8M |
| Operating margin | −8678.2% | −17416.5% | −159.4% | −755.9% | −184.8% | −540.9% | −1116.9% | — | −2377.6% | — |
| Net income | −$16.4M | −$16.1M | −$7.91M | −$13.0M | −$8.50M | −$13.0M | −$19.2M | −$20.3M | −$18.5M | −$27.0M |
| Net margin | −2579.2% | −5547.8% | −63.6% | −471.9% | −132.5% | −324.3% | −949.7% | — | −1815.3% | — |
| Balance sheet | ||||||||||
| Cash and equivalents | $51.5M | $11.8M | $1.68M | $1.78M | $5.75M | $13.4M | $12.1M | $9.45M | $36.7M | $88.9M |
| Total assets | $54.5M | $27.9M | $8.56M | $9.27M | $14.8M | $25.5M | $33.2M | $11.0M | $38.3M | $89.9M |
| Total liabilities | $22.9M | $47.5M | $28.9M | $18.1M | $11.0M | $10.3M | $27.4M | $29.6M | $24.0M | $25.5M |
| Long-term debt | $11.1M | — | $15.1M | $5.04M | — | — | — | — | — | — |
| Shareholders' equity | −$90.9M | −$151.0M | −$82.9M | −$49.0M | −$80.1M | −$9.74M | −$10.7M | −$24.7M | $12.2M | $64.4M |
| Cash flow | ||||||||||
| Operating cash flow | −$48.2M | −$44.6M | −$26.9M | −$23.0M | −$18.0M | −$19.3M | −$16.0M | −$19.1M | −$25.3M | −$25.3M |
| Capital expenditure | $87.0K | $57.0K | $5.00K | $70.0K | $0 | $0 | $21.0K | $0 | $0 | — |
| Free cash flow | −$48.3M | −$44.6M | −$26.9M | −$23.1M | −$18.0M | −$19.3M | −$16.0M | −$19.1M | −$25.3M | — |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $0 | $0 | $0 | — | $36.8M | $0 |
| Growth (year over year) | — | — | −100.0% | — | — | — | — | — |
| Operating income | −$6.51M | — | −$6.50M | −$7.72M | −$10.7M | — | $23.3M | −$13.9M |
| Operating margin | — | — | — | — | — | — | 63.1% | — |
| Net income | −$4.78M | — | −$5.09M | −$6.05M | −$8.70M | — | $24.1M | −$13.1M |
| Net margin | — | — | — | — | — | — | 65.5% | — |
| Balance sheet | ||||||||
| Cash and equivalents | $41.6M | $36.7M | $31.1M | $25.9M | $98.5M | $88.9M | $98.1M | $86.6M |
| Total assets | $43.2M | $38.3M | $32.0M | $26.4M | $99.5M | $89.9M | $98.8M | $87.6M |
| Total liabilities | $25.3M | $24.0M | $23.1M | $24.0M | $29.0M | $25.5M | $8.85M | $8.96M |
| Shareholders' equity | $15.0M | $12.2M | $7.92M | $2.76M | $70.5M | $64.4M | $90.0M | $78.6M |
| Cash flow | ||||||||
| Operating cash flow | −$6.42M | — | −$5.69M | −$5.09M | −$5.22M | — | $9.15M | −$11.4M |
From vTv Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
About vTv Therapeutics
- Headquarters
- High Point, North Carolina From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International